Morepen Laboratories (NSE:MOREPENLAB) Beneish M-Score: -2.02 (As of Jun. 27, 2026)


NSE:MOREPENLAB Morepen Laboratories Ltd NSE:MOREPENLAB
74 GF Score
Price ₹53.16
GF Value ₹49.82
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Morepen Laboratories Beneish M-Score?

Morepen Laboratories NSE:MOREPENLAB +2.00% 74 Beneish M-Score is -2.02 as of Jun. 27, 2026. GuruFocus rates NSE:MOREPENLAB with a GF Score™ of 74/100 and a GF Value™ of ₹49.82 (Fairly Valued). The stock has 5 warning signs investors should review. Among 911 Drug Manufacturers companies, Morepen Laboratories ranks worse than 77.5% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.02 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Morepen Laboratories's Beneish M-Score or its related term are showing as below:

NSE:MOREPENLAB' s Beneish M-Score Range Over the Past 10 Years
Min: -2.66   Med: -2.14   Max: -1.43
Current: -2.02

During the past 13 years, the highest Beneish M-Score of Morepen Laboratories was -1.43. The lowest was -2.66. And the median was -2.14.


Morepen Laboratories Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Morepen Laboratories's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Morepen Laboratories Beneish M-Score Chart

Morepen Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.43 -1.92 -2.34 -2.05 -2.02

Morepen Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.05 0.00 0.00 0.00 -2.02

NSE:MOREPENLAB vs ZTS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Morepen Laboratories's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Morepen Laboratories Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Morepen Laboratories's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Morepen Laboratories's Beneish M-Score falls into.


NSE:MOREPENLAB
74GF Score
Morepen Laboratories Ltd NSE:MOREPENLAB
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Morepen Laboratories Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Morepen Laboratories for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0217+0.528 * 0.9529+0.404 * 2.0254+0.892 * 0.9968+0.115 * 0.74
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.2414+4.679 * 0.032144-0.327 * 1.0685
=-2.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ₹3,336 Mil.
Revenue was ₹18,057 Mil.
Gross Profit was ₹6,823 Mil.
Total Current Assets was ₹11,636 Mil.
Total Assets was ₹19,361 Mil.
Property, Plant and Equipment(Net PPE) was ₹4,156 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹364 Mil.
Selling, General, & Admin. Expense(SGA) was ₹990 Mil.
Total Current Liabilities was ₹4,903 Mil.
Long-Term Debt & Capital Lease Obligation was ₹1,379 Mil.
Net Income was ₹949 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹326 Mil.
Total Receivables was ₹3,276 Mil.
Revenue was ₹18,116 Mil.
Gross Profit was ₹6,523 Mil.
Total Current Assets was ₹11,594 Mil.
Total Assets was ₹17,781 Mil.
Property, Plant and Equipment(Net PPE) was ₹4,569 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹290 Mil.
Selling, General, & Admin. Expense(SGA) was ₹800 Mil.
Total Current Liabilities was ₹5,007 Mil.
Long-Term Debt & Capital Lease Obligation was ₹392 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(3335.926 / 18056.915) / (3275.657 / 18115.758)
=0.184745 / 0.180818
=1.0217

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(6522.686 / 18115.758) / (6822.75 / 18056.915)
=0.360056 / 0.377847
=0.9529

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (11636.141 + 4155.949) / 19361.201) / (1 - (11593.717 + 4568.956) / 17780.993)
=0.184343 / 0.091014
=2.0254

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=18056.915 / 18115.758
=0.9968

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(289.817 / (289.817 + 4568.956)) / (364.347 / (364.347 + 4155.949))
=0.059648 / 0.080602
=0.74

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(989.76 / 18056.915) / (799.863 / 18115.758)
=0.054813 / 0.044153
=1.2414

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1378.614 + 4903.021) / 19361.201) / ((392.422 + 5006.536) / 17780.993)
=0.324444 / 0.303636
=1.0685

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(948.768 - 0 - 326.42) / 19361.201
=0.032144

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Morepen Laboratories has a M-score of -2.02 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.02 mean?
Morepen Laboratories (NSE:MOREPENLAB) has a Beneish M-Score of -2.02 as of Jun. 27, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Morepen Laboratories and its competitors. According to the industry distribution chart, Morepen Laboratories ranks #706 out of 911 companies in the Drug Manufacturers industry, placing it in the top 77.5%.
Is Morepen Laboratories' Beneish M-Score too high?
Morepen Laboratories' current Beneish M-Score is -2.02. Based on the distribution chart, Morepen Laboratories ranks #706 out of 911 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Morepen Laboratories has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Morepen Laboratories' Beneish M-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Morepen Laboratories ranks #706 out of 911 companies for Beneish M-Score. This places Morepen Laboratories in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Morepen Laboratories and its competitors. Morepen Laboratories's current Beneish M-Score is -2.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Morepen Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Morepen Laboratories (NSE:MOREPENLAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹49.82, compared to a current price of ₹53.16 — trading 6.7% above its estimated fair value. The current Beneish M-Score is -2.02. Morepen Laboratories' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Morepen Laboratories (NSE:MOREPENLAB), the current Beneish M-Score is -2.02 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Morepen Laboratories (NSE:MOREPENLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Morepen Laboratories stock appears to be overvalued. The current stock price of ₹53.16 is trading 6.7% above its estimated GF Value™ of ₹49.82. GuruFocus considers Morepen Laboratories to be Fairly Valued.

Key valuation signals for NSE:MOREPENLAB:

  • Beneish M-Score: -2.02
  • GF Value™: ₹49.82 vs. price of ₹53.16 (6.7% above fair value)
  • GF Score™: 74/100 with 5 warning signs

No single metric tells the full story. See the NSE:MOREPENLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Morepen Laboratories Business Description

Other Exchanges 500288:India
Address Udyog Vihar-III, Sector-20, 2nd Floor, Tower C, DLF Cyber Park, Gurugram, HR, IND, 122016
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.
74GF Score

Get the complete analysis for NSE:MOREPENLAB

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹53.16
Price
₹49.82
GF Value